Google Advertisement
Jakarta — PT Siloam International Hospitals Tbk (SILO), the Lippo Group’s healthcare arm, reported a net profit of Rp 1.1 trillion for fiscal year 2025, signaling a decisive shift toward premium medical services and advanced technology.
The announcement came during the company’s Annual General Meeting of Shareholders (RUPST) on May 12, 2026, where executives outlined a strategy to reinvest earnings rather than distribute dividends.
Financial Resilience Amid Transition
Siloam’s revenue rose 5.2 percent year-on-year to Rp 12.8 trillion, while EBITDA surged 18.3 percent to Rp 2.8 trillion.
Google Advertisement
President Director David Utama described 2025 as a transitional year, with the company balancing operational efficiency and clinical innovation.
“We are strengthening our premium network while ensuring value-based care remains accessible,” he said.
The decision to retain profits reflects a long-term growth plan, prioritizing reinvestment in infrastructure, technology, and specialized services.
Premium and Value Networks
Siloam’s dual strategy rests on two pillars:
Premium Network: Partnerships with international hospitals, enhanced patient experience, and cutting-edge medical technology.
Value Seeker Network: Operational efficiency and affordable healthcare access.
The company’s Next Gen Siloam (NGS) program aims to align clinical capabilities, capital allocation, and operational resources across its nationwide hospital network.
Expansion Projects
Recent expansions highlight Siloam’s ambition to reduce reliance on overseas treatment.
Surabaya Mochtar Riady Center for Advanced Care (MRCAC): A flagship facility offering advanced clinical services.
Makassar Expansion: Soft launch featuring new medical technologies, including Asia’s first integrated CT-LINAC system for precision oncology.
Executives emphasized that these investments are designed to keep Indonesian patients at home by offering international-standard care domestically.
The company’s governance structure was reaffirmed at the shareholder meeting.
The Board of Directors, led by David Utama, includes Atiff Ibrahim Gill, Benny Haryanto Djie, Gabriele Isacco Tironi, Phua Meng Kuan (Daniel Phua), Richard Kidarsa, and Surya Tatang.
The Board of Commissioners is chaired by Yasonna H. Laoly, alongside Andy Nugroho Purwohardono, Sigit Prasetya, James Tobias Hall, and Bambang Soesatyo.
Siloam’s Rp 1.1 trillion profit underscores the growing demand for premium healthcare in Indonesia.
By channeling earnings into reinvestment, the company is positioning itself as a leader in oncology and advanced medical services.Analysts suggest this strategy could reshape the country’s healthcare landscape, reducing outbound medical tourism and elevating domestic standards.
As Indonesia’s middle class expands and expectations for healthcare rise, Siloam’s bet on premium services may prove pivotal in defining the next era of medical care in the region.
